1 Min Read
June 16 (Reuters) - Antisense Therapeutics Ltd
* Phase II study has shown atl1102 significantly reduces number of active MS lesions that convert to "black holes" Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.